Get the Stockscreener App
19.10
2.50%
-0.49
After Hours:
19.10
Arvinas Inc Stock (ARVN) Latest News
Barclays Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Leerink cuts Arvinas stock price target to $49 from $62 - MSN
Arvinas's SWOT analysis: biotech stock awaits pivotal trial results - Investing.com India
Long Term Trading Analysis for (ARVN) - Stock Traders Daily
Arvinas Holding: Buy Rating Anticipates Major Upside from VERITAC-2 and PROTACs - TipRanks
Arvinas’s SWOT analysis: biotech stock awaits pivotal trial results By Investing.com - Investing.com Nigeria
Arvinas's SWOT analysis: biotech stock awaits pivotal trial results By Investing.com - Investing.com Australia
Leerink cuts Arvinas stock price target to $49 from $62 By Investing.com - Investing.com Canada
Arvinas stock plunges to 52-week low at $16.95 amid market challenges - MSN
Arvinas (NASDAQ:ARVN) Reaches New 52-Week Low After Analyst Downgrade - MarketBeat
ARVNArvinas, Inc Latest Stock News & Market Updates - StockTitan
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 - The Manila Times
Arvinas, Inc. to Host Live Webcast for Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 11, 2025 - Nasdaq
SG Americas Securities LLC Grows Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Citadel Advisors LLC's Strategic Acquisition of Arvinas Inc. Sha - GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PrimePublishers.com
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
When the Price of (ARVN) Talks, People Listen - Stock Traders Daily
The Escalator: Merck, Novartis, Arvinas and more - MM+M Online
Brokers Set Expectations for Arvinas FY2025 Earnings - MarketBeat
Arvinas terminates lease agreement, frees up future liabilities - Investing.com India
Arvinas terminates lease agreement, frees up future liabilities By Investing.com - Investing.com Australia
Arvinas Holding Company Adjusts Real Estate Strategy - TipRanks
Assenagon Asset Management S.A. Buys 777 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas looks for new chief commercial officer - The Pharma Letter
Arvinas Repeat Insider Selling Not A Positive Indicator - Simply Wall St
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - The Motley Fool
Arvinas, Inc. (NASDAQ:ARVN) Receives $63.50 Average PT from Analysts - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains? - MSN
Arvinas (NASDAQ:ARVN) Sets New 12-Month LowShould You Sell? - MarketBeat
Arvinas stock touches 52-week low at $17.35 amid market challenges - Investing.com Australia
Arvinas outlines 2025 clinical trial plans for breast cancer drug By Investing.com - Investing.com Australia
Arvinas Announces Updates on Clinical Trials Progress - TipRanks
Arvinas outlines 2025 clinical trial plans for breast cancer drug - Investing.com India
Arvinas Updates Guidance for First- and Second-Line Phase 3 - GlobeNewswire
Arvinas Plans Two Phase 3 Trials for Breakthrough Breast Cancer Drug, Expands Pipeline for 2025 - StockTitan
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update - Business Upturn
Metastatic Prostate Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion Corporation - Barchart
Metastatic Prostate Cancer Market to Expand Significantly - openPR
JPMorgan Chase & Co. Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
JPMorgan Chase & Co. Increases Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas (NASDAQ:ARVN) Trading 9.2% HigherHere's Why - MarketBeat
How To Trade (ARVN) - Stock Traders Daily
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):